Cubist Systematic Strategies LLC Lowers Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Cubist Systematic Strategies LLC reduced its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 55.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 463,685 shares of the biotechnology company’s stock after selling 567,758 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in ADMA Biologics were worth $5,184,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of ADMA. Quest Partners LLC acquired a new stake in shares of ADMA Biologics in the 2nd quarter valued at approximately $29,000. EntryPoint Capital LLC acquired a new stake in shares of ADMA Biologics in the 1st quarter valued at approximately $31,000. CWM LLC lifted its holdings in shares of ADMA Biologics by 114.2% in the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after buying an additional 4,367 shares during the period. Acadian Asset Management LLC acquired a new stake in shares of ADMA Biologics in the 2nd quarter valued at approximately $93,000. Finally, Viewpoint Capital Management LLC lifted its holdings in shares of ADMA Biologics by 18.6% in the 1st quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 2,416 shares during the period. 75.68% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the transaction, the director now owns 153,941 shares in the company, valued at $2,843,290.27. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the sale, the director now owns 153,941 shares in the company, valued at $2,843,290.27. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 466,900 shares of company stock worth $8,224,121. 3.70% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages recently issued reports on ADMA. Mizuho lifted their price objective on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. Finally, HC Wainwright lifted their price objective on ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, August 12th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $15.50.

ADMA Biologics Price Performance

ADMA stock opened at $19.39 on Friday. The stock has a 50-day moving average price of $16.27 and a two-hundred day moving average price of $11.30. ADMA Biologics, Inc. has a 12-month low of $3.06 and a 12-month high of $20.16. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74. The company has a market cap of $4.49 billion, a PE ratio of -969.50 and a beta of 0.61.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The company had revenue of $107.20 million during the quarter, compared to the consensus estimate of $86.44 million. During the same quarter in the prior year, the business earned ($0.02) earnings per share. The company’s revenue was up 78.4% compared to the same quarter last year. As a group, research analysts predict that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.